Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B. It also offers artificial intelligence platform for drug development. Tevogen Inc. was formerly known as Tevogen Bio Holdings Inc. and changed its name to Tevogen Inc. in July 2026. The company was incorporated in 2020 and is headquartered in Warren, New Jersey.…
Tevogen Highlights Significant Liability Reduction and Continued Insider Control
Tevogen (NASDAQ: TVGN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 18 employees.
The shares were at 5.900 USD on 20 November 2026, down 74.8% over 52 weeks. Its 52-week range is 3.636 USD to 25.10 USD: the price is 76.5% below the high and 62.2% above the low.
Its market capitalisation is 405.20M USD.
Tevogen reports return on equity of 319.1% and an operating margin of 0.0%.
Its debt exceeds its cash by 8.36M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 30 March 2027.